ArticleFrontiers in psychiatry2025
Five differentially expressed proteins identified to serve as potential blood biomarkers for schizophrenia screening based on proteomics.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Schizophrenia is a multifactorial neuropsychiatric disorder characterized by a wide range of debilitating symptoms and relatively poor clinical outcome, bringing a huge burden of disease. However, the underlying pathological mechanism of this disease remains unclear. We aimed to use mass spectrometry to complete proteomics analysis to find biomarkers related to schizophrenia in peripheral blood, which can provide some biomarker for the pathology, diagnosis or treatment of schizophrenia and the focus of future research. Methods: This study was a cross-sectional case-control study involving 46 patients with schizophrenia and 43 healthy controls. All subjects provided early morning fasting cubital venous blood, completed the collection of general demographic data and clinical scale evaluation. At last, the blood samples of all subjects were subjected to mass spectrometry analysis, combined with bioinformatics analysis, to identify and screen differential proteins. Results: Using nominal P<0.05 (uncorrected) and fold change > 1.5 or < 0.67, 34 proteins were prioritized, among which 22 proteins were up-regulated and 12 were down-regulated; these candidates require false discovery rate controlled verification. Gene ontology over-representation analysis suggested trends in cellular component organization and cell adhesion molecule binding, with no false discovery rate correction. Kyoto encyclopedia of genes and genomes functional enrichment analysis showed that the differential proteins were mainly involved in mitogen-activated protein kinase signaling pathways. Discussion: Our research indicates that neural cell adhesion molecule L1, integrin alpha-M, alpha-actinin-1, filamin-A and profilin-1 which are associated with cytoskeleton, synapse and immunity were preliminarily screened as candidate protein markers for schizophrenia. Moreover, mitogen-activated protein kinase signaling pathway may be related to the pathology of schizophrenia, and PI3K-Akt signaling pathway may be related to the efficacy and side effects of antipsychotic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.